Subscribe
Sign in
Home
Archive
Leaderboard
About
Who Wins (and Loses) in Pharma’s Latest GLP-1 Power Play?
Novo's surprising partnerships, disruptive NHS whispers, and a fresh shift in employer economics could redefine the D2C landscape.
May 4
•
Ashwin Sharma, MD
3
Share this post
GLP-1 Digest
Who Wins (and Loses) in Pharma’s Latest GLP-1 Power Play?
Copy link
Facebook
Email
Notes
More
Is Your GLP-1 Strategy Future-Proof?
Six rapid-fire shifts every founder, operator, and investor needs to know
Apr 27
•
Ashwin Sharma, MD
2
Share this post
GLP-1 Digest
Is Your GLP-1 Strategy Future-Proof?
Copy link
Facebook
Email
Notes
More
Why Your Ozempic Won't Cost More–Even With a 200% Tariff
With Novo and Lilly locked in a market share battle, neither can risk price hikes—even with tariffs looming
Apr 24
•
Ashwin Sharma, MD
3
Share this post
GLP-1 Digest
Why Your Ozempic Won't Cost More–Even With a 200% Tariff
Copy link
Facebook
Email
Notes
More
1
The Real Reason Weight-Loss Drugs Fail
and why your business model might collapse with it.
Apr 4
•
Ashwin Sharma, MD
5
Share this post
GLP-1 Digest
The Real Reason Weight-Loss Drugs Fail
Copy link
Facebook
Email
Notes
More
2
The Suffering Economy is Over
Weight-loss meds threaten a $300 billion industry built on shame. That’s exactly why we need them.
Mar 13
•
Ashwin Sharma, MD
3
Share this post
GLP-1 Digest
The Suffering Economy is Over
Copy link
Facebook
Email
Notes
More
Coming soon
This is GLP-1 Digest .
Feb 11
•
Ashwin Sharma, MD
Share this post
GLP-1 Digest
Coming soon
Copy link
Facebook
Email
Notes
More
GLP-1 Digest
Essays on the future of GLP-1s—shaped by startups, science, and tech.
Subscribe
GLP-1 Digest
Subscribe
About
Archive
Sitemap
Share this publication
theglp1weeklydigest
GLP-1 Digest
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts